Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
← catalyst calendarNCT03647878 · readout in 407 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
224actual
Sites
82
Countries
Austria, Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-24 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Primary outcomes
what the primary-completion date above is the date OFThe proportion of subjects with dose reduction of cabozantinib due to Serious Adverse Events/Adverse Events (SAEs/AEs)
measured 2 years
The proportion of subjects with dose interruption of cabozantinib and/or nivolumab due to SAEs/AEs
measured 2 years
The proportion of subjects with termination of cabozantinib /cabozantinib-nivolumab combination due to SAEs/AEs
measured 2 years
Number of injection delayed of nivolumab due to SAE/AE
measured 2 years
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed